Literature DB >> 11138683

Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.

F Moog1, R Linke, N Manthey, R Tiling, P Knesewitsch, K Tatsch, K Hahn.   

Abstract

UNLABELLED: The objective of this prospective study was to determine the extent to which the levels of thyroid-stimulating hormone (TSH) influence the uptake of FDG by thyroid carcinoma tumors
METHODS: Ten patients with follicular (n = 7) or papillary (n = 3) thyroid carcinoma underwent FDG PET during TSH suppression (<0.05 microU/mL) and TSH stimulation (>22 microU/mL) within an average interval of 42 d (range, 28-73 d). The findings were evaluated by visual criteria. In addition, a tumor-to-background ratio (TBR) was determined for 17 lesions that were visualized.
RESULTS: In 15 of 17 lesions with positive FDG uptake, TSH stimulation was associated with an increase in the TBR from 3.85 +/- 2.53 (mean +/- SD) to 5.84 +/- 4.84, corresponding to an average increase of 63.1% (P < 0.001). Determination of absolute counting rates indicated that this increase was the result of a decrease in FDG metabolism in the background together with an increase in the tumor tissue. No relationship was found between the presence or absence of iodine storage capacity (5 versus 12/17 lesions) and increase in FDG accumulation. Seven of 10 patients had additional iodine-positive metastases that showed no accumulation of FDG.
CONCLUSION: Most locally recurrent and metastatic follicular and papillary thyroid carcinomas exhibited a significant increase in FDG uptake on TSH stimulation. In 3 of 10 patients, TSH stimulation resulted in either detection of new lesions or classification of the FDG uptake pattern as typical for malignancy. These findings suggest that FDG uptake in recurrent and metastatic thyroid carcinoma depends on the TSH level. Therefore, we recommend that PET examinations be performed in patients with thyroid carcinoma under TSH stimulation and follow-up examinations be performed under identical TSH conditions to prevent erroneous interpretation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11138683

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

Review 1.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

2.  Clinical Usefulness of F-18 FDG PET/CT in Papillary Thyroid Cancer with Negative Radioiodine Scan and Elevated Thyroglobulin Level or Positive Anti-thyroglobulin Antibody.

Authors:  Su Jung Choi; Kyung Pyo Jung; Sun Seong Lee; Yun Soo Park; Seok Mo Lee; Sang Kyun Bae
Journal:  Nucl Med Mol Imaging       Date:  2015-10-22

3.  Recombinant TSH-stimulated, radioguided differentiated thyroid carcinoma surgery.

Authors:  Michael E Spieth; Steven B Standiford; Marjorie E Starkman; John Gough
Journal:  Clin Med Res       Date:  2003-01

Review 4.  The role of 18F-fluorodeoxyglucose positron emission tomography in thyroid neoplasms.

Authors:  Brian Hung-Hin Lang; Tsz Ting Law
Journal:  Oncologist       Date:  2011-03-04

Review 5.  Role of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative ¹³¹I scan: review of the literature.

Authors:  Francesco Bertagna; Giorgio Biasiotto; Emanuela Orlando; Giovanni Bosio; Raffaele Giubbini
Journal:  Jpn J Radiol       Date:  2010-11-27       Impact factor: 2.374

6.  Optimal threshold of stimulated serum thyroglobulin level for 18F-FDG PET/CT imaging in patients with thyroid cancer.

Authors:  Hong Chai; Hu Zhang; Yong-Li Yu; Yun-Chao Gao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-06-06

7.  Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?

Authors:  Michael Zoller; Susanne Kohlfuerst; Isabel Igerc; Ewald Kresnik; Hans-Jürgen Gallowitsch; Iris Gomez; Peter Lind
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-14       Impact factor: 9.236

8.  The value of positron emission tomography in the surgical management of recurrent papillary thyroid carcinoma.

Authors:  Clive S Grant; Geoffrey B Thompson; David R Farley; Melanie L Richards; Brian P Mullan; Ian D Hay
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

9.  Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.

Authors:  Masahiro Iwata; Kanji Kasagi; Takashi Misaki; Keiichi Matsumoto; Yasuhiro Iida; Takayoshi Ishimori; Yuji Nakamoto; Tatsuya Higashi; Tsuneo Saga; Junji Konishi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-10       Impact factor: 9.236

10.  Influence of TSH on uptake of [18F]fluorodeoxyglucose in human thyroid cells in vitro.

Authors:  J T Deichen; C Schmidt; O Prante; S Maschauer; T Papadopoulos; T Kuwert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.